|
Post by RLC on Jan 5, 2015 14:31:05 GMT
Well that was a pretty exciting call. All of the analysts seemed pretty blown away by the data as did I. I definitely plan to get back in here at some point. Wouldn't be surprised to see this one continue to appreciate in the near term. They have a legit treatment for ALS and are moving along full steam ahead. Pretty much my take as well. I still have a small amount at what now seems like a very low cost basis, but I'll also be looking to add to my position in the near term.
|
|
|
Post by JHam on Jan 5, 2015 14:33:30 GMT
I stepped away for just a second and got back in time to hear someone cut him off. What exactly did he say? He was asked if this data would allow them to start getting serious with big pharma about partnerships or licensure, and Tony said; Yes we have been talking with several companies and <suddenly interupted by Lebovits> Sorry we can't comment any further on that now.
|
|
|
Post by RLC on Jan 5, 2015 14:38:38 GMT
Wow. PPS dropping fast! I'm sure we'll stay above $5......... ?
|
|
|
Post by RLC on Jan 5, 2015 14:39:04 GMT
I stepped away for just a second and got back in time to hear someone cut him off. What exactly did he say? He was asked if this data would allow them to start getting serious with big pharma about partnerships or licensure, and Tony said; Yes we have been talking with several companies and <suddenly interupted by Lebovits> Sorry we can't comment any further on that now. Thanks for clarifying this JHam!
|
|
|
Post by avtech on Jan 5, 2015 14:41:34 GMT
Toward the end a commitment was made for a future conference call in "a few weeks"...then also mentioned a few months. That combined with the earlier potential jv conversation being shut down sounds like the first quarter could be very profitable for holders.
|
|
|
Post by JHam on Jan 5, 2015 14:43:34 GMT
I was looking to start adding again in the mid $5s. If it keeps dropping like this I'll probably wait.
|
|
|
Post by lcd on Jan 5, 2015 14:46:02 GMT
I don't understand exactly what Chaim Lebovits does as President (did they just create the position for him since he invested so much money?) but that guy was really excited about the results. I thought that was a great call so I put in some buy orders for $5.50 if it gets that low today. I fear the share price will drift down like it did all fall without any news but I think it is worth the risk to put at least all my profits back in.
|
|
|
Post by JHam on Jan 5, 2015 14:50:22 GMT
Toward the end a commitment was made for a future conference call in "a few weeks"...then also mentioned a few months. That combined with the earlier potential jv conversation being shut down sounds like the first quarter could be very profitable for holders. I think even if Tony mentioned them being in talks with big pharma, they are still a bit away before inking any partnership deals. Well, deals that would include lots of upfront cash and would be beneficial to shareholders. It does seem like we should hear about the next indication in the next few weeks. Sometimes "a few weeks" in biotech land means 6 months. What I liked about this call and what makes me want to stay close is 1) The data is spectacular. I think it is safe to say we have never seen such dramatic results for an ALS treatment ever. 2) They are going to get this data published and go on the conference circuit boasting this data, and I believe it is likely to garner some real attention from investors. 3) I think they are a serious candidate for breakthrough status designation once they provide some Phase 2 data.
|
|
|
Post by JHam on Jan 5, 2015 14:55:37 GMT
I don't understand exactly what Chaim Lebovits does as President (did they just create the position for him since he invested so much money?) but that guy was really excited about the results. I thought that was a great call so I put in some buy orders for $5.50 if it gets that low today. I fear the share price will drift down like it did all fall without any news but I think it is worth the risk to put at least all my profits back in. Chaim is the company and has always been President. It became Brainstorm and exists on his dime. He is basically an oil guy (which is what the real focus of ACCTB is) and not a Biotech-CEO type. While he is smart and obviously now knows a lot about the sector, I don't think that is where his skill set lies. He needed someone who knew how to be CEO of a biotech company, i.e. was fluent in regulatory language for talks with the FDA among other things.
|
|
|
Post by JHam on Jan 5, 2015 15:07:41 GMT
So I ended up selling in tranches of three at $8.25, $7.75, and $6.90 for a total average of $7.63 or 118% realized gain. Not a bad way to start off the year A big thanks to everyone's contributions/DD with this stock the past few months. Great example of working together and being able capitalize from our information sharing. This is the second win for this board in the span of one month if you count the nice run up with ONCS in December. Only most of us forgot to sell that one, lol
|
|
|
Post by JHam on Jan 5, 2015 15:11:18 GMT
Thank you for this play, JHam! I jumped in on June 7th, 2014, and rode it down for the rest of the year. I almost closed the position in December to grab a tax loss, but decided to wait for the conference call per this board's anticipation of a positive move up with the conference call. Just pulled my full position pre-market @$7.90 for a 40% gain, and will likely put it back in to avoid short term capital gains. Thanks again, BCLI would have been off my radar forever! Well done brnhut! Not just me, but thanks to everyone who helped with DD and information sharing with this one. The story is not over yet with this company, this is just Chapter 1. It is gonna be a fun one to watch from here on out.
|
|
|
Post by selluwud on Jan 5, 2015 15:17:13 GMT
So I ended up selling in tranches of three at $8.25, $7.75, and $6.90 for a total average of $7.63 or 118% realized gain. Not a bad way to start off the year A big thanks to everyone's contributions/DD with this stock the past few months. Great example of working together and being able capitalize from our information sharing. This is the second win for this board in the span of one month if you count the nice run up with ONCS in December. Only most of us forgot to sell that one, lol Great job, any profit is good profit. I sold half my holdings at 7.50 and will wait it out for a new entry price to increase my share count. I know you have posted it somewhere buried in this thread, but how soon will they need a capital raise?
|
|
|
Post by RLC on Jan 5, 2015 15:17:47 GMT
So I ended up selling in tranches of three at $8.25, $7.75, and $6.90 for a total average of $7.63 or 118% realized gain. Not a bad way to start off the year A big thanks to everyone's contributions/DD with this stock the past few months. Great example of working together and being able capitalize from our information sharing. This is the second win for this board in the span of one month if you count the nice run up with ONCS in December. Only most of us forgot to sell that one, lol Great job JHam! Didn't do as good as you, but I feel good about my trades here. Sold at $4.90, $6.10, $7.10, $8, $7.83, and $6.69 for a total average of $6.77 or almost exactly a 100% realized gain. No complaints from me
|
|
|
Post by JHam on Jan 5, 2015 15:27:57 GMT
So I ended up selling in tranches of three at $8.25, $7.75, and $6.90 for a total average of $7.63 or 118% realized gain. Not a bad way to start off the year A big thanks to everyone's contributions/DD with this stock the past few months. Great example of working together and being able capitalize from our information sharing. This is the second win for this board in the span of one month if you count the nice run up with ONCS in December. Only most of us forgot to sell that one, lol Great job JHam! Didn't do as good as you, but I feel good about my trades here. Sold at $4.90, $6.10, $7.10, $8, $7.83, and $6.69 for a total average of $6.77 or almost exactly a 100% realized gain. No complaints from me Great job RLC! Are you completely out now?
|
|
|
Post by JHam on Jan 5, 2015 15:31:31 GMT
So I ended up selling in tranches of three at $8.25, $7.75, and $6.90 for a total average of $7.63 or 118% realized gain. Not a bad way to start off the year A big thanks to everyone's contributions/DD with this stock the past few months. Great example of working together and being able capitalize from our information sharing. This is the second win for this board in the span of one month if you count the nice run up with ONCS in December. Only most of us forgot to sell that one, lol Great job, any profit is good profit. I sold half my holdings at 7.50 and will wait it out for a new entry price to increase my share count. I know you have posted it somewhere buried in this thread, but how soon will they need a capital raise? Nice job locking in profits at $7.50. They should have about $8M in cash right about which would get them through the next few quarters. However, I don't see them waiting at long. Especially with data this good. They might as well take advantage of the chance when they can. I took the comments about them compiling the data and presenting it at upcoming conferences to mean they will be shopping around for investors for the next offering.
|
|
|
Post by selluwud on Jan 5, 2015 15:34:08 GMT
Great job, any profit is good profit. I sold half my holdings at 7.50 and will wait it out for a new entry price to increase my share count. I know you have posted it somewhere buried in this thread, but how soon will they need a capital raise? Nice job locking in profits at $7.50. They should have about $8M in cash right about which would get them through the next few quarters. However, I don't see them waiting at long. Especially with data this good. They might as well take advantage of the chance when they can. I took the comments about them compiling the data and presenting it at upcoming conferences to mean they will be shopping around for investors for the next offering. Thanks JHam, I'm sticking my finger in the air now trying to get a read on a re-entry price??
|
|
|
Post by JHam on Jan 5, 2015 15:41:41 GMT
Nice job locking in profits at $7.50. They should have about $8M in cash right about which would get them through the next few quarters. However, I don't see them waiting at long. Especially with data this good. They might as well take advantage of the chance when they can. I took the comments about them compiling the data and presenting it at upcoming conferences to mean they will be shopping around for investors for the next offering. Thanks JHam, I'm sticking my finger in the air now trying to get a read on a re-entry price?? I think anything under $100M market cap is a long term bargain with this company. I do believe dilution is around the corner and would rather not be around for that. Although I wouldn't have felt that way if we were still in the $4s. It is tough to tell if this thing will jump back up to $7 and continue upward or if things will stabilize lower first before gradually creeping back up. Either could happen.
|
|
|
Post by RLC on Jan 5, 2015 15:52:06 GMT
Great job JHam! Didn't do as good as you, but I feel good about my trades here. Sold at $4.90, $6.10, $7.10, $8, $7.83, and $6.69 for a total average of $6.77 or almost exactly a 100% realized gain. No complaints from me Great job RLC! Are you completely out now? Thanks JHam! Still holding 10% of my original investment that I'll likely hold on to for the foreseeable future.
|
|
|
Post by tunis on Jan 5, 2015 19:49:35 GMT
I made a nice 50% profit in this earlier in my retirement account. They had two patients die which is why I'm thinking this is dropping.
Twelve ALS patients were evaluable for response. Of these, 11 patients showed a slowing of ALS disease progression at six months compared to baseline, measured either by improved ALSFRS or lung function scores, Brainstorm said. Two other patients enrolled in the study died. Administration of the NurOwn therapy was well tolerated by patients, the company said
|
|
|
Post by RLC on Jan 5, 2015 20:00:44 GMT
I made a nice 50% profit in this earlier in my retirement account. They had two patients die which is why I'm thinking this is dropping. Twelve ALS patients were evaluable for response. Of these, 11 patients showed a slowing of ALS disease progression at six months compared to baseline, measured either by improved ALSFRS or lung function scores, Brainstorm said. Two other patients enrolled in the study died. Administration of the NurOwn therapy was well tolerated by patients, the company said I personally feel this is a "sell the news" drop, as Adam Feuerstein said: " Brainstorm shares are down over 20% to about $6 Monday but that's more of an expected, sell-on-the-news reaction than a negative referendum on the updated, final results from the NurOwn phase IIa study. Brainstorm's stock price more than doubled in the previous eight trading days, so profit taking on today's data announcement isn't surprising at all." This is a condition in which it's almost expected to have some patients participating in early stage (safety) trials die. Very sad to say...
|
|